Regeneron Pharmaceuticals’ (REGN) “Hold” Rating Reaffirmed at Piper Jaffray Cos.
Piper Jaffray Cos. reissued their hold rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research report sent to investors on Tuesday morning. The firm currently has a $447.00 target price on the biopharmaceutical company’s stock.
Several other brokerages have also commented on REGN. Vetr raised Regeneron Pharmaceuticals from a buy rating to a strong-buy rating and set a $429.64 price target on the stock in a research note on Monday, June 13th. Sanford C. Bernstein reaffirmed a buy rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 30th. Leerink Swann reiterated an outperform rating and issued a $530.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 1st. Canaccord Genuity reiterated a hold rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Finally, Wells Fargo & Co. reiterated a hold rating on shares of Regeneron Pharmaceuticals in a report on Monday, May 23rd. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $470.91.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.50% on Tuesday, hitting $408.29. The stock had a trading volume of 32,404 shares. The company has a market cap of $42.72 billion, a PE ratio of 63.70 and a beta of 1.24. Regeneron Pharmaceuticals has a 12 month low of $329.09 and a 12 month high of $592.59. The company has a 50-day moving average of $408.70 and a 200 day moving average of $389.50.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the prior year, the company posted $2.89 EPS. The company’s quarterly revenue was up 21.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $10.93 EPS for the current fiscal year.
In other news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the transaction, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 10.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. IFP Advisors Inc increased its position in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares during the period. Advisory Services Network LLC increased its position in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $140,000. Brave Asset Management Inc acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $157,000. Finally, Bessemer Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares during the period. 68.16% of the stock is owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.